Page 43 - Ovarian Cancer Surgery - Quality Indicators
P. 43
147. Muggia, F.M., et al. Phase III randomized 155. Pfisterer, J., et al. Randomized phase III
study of cisplatin versus paclitaxel versus trial of topotecan following carboplatin
cisplatin and paclitaxel in patients with and paclitaxel in first-line treatment of
suboptimal stage III or IV ovarian cancer: advanced ovarian cancer: a gynecologic
a gynecologic oncology group study. J cancer intergroup trial of the AGO-OVAR
Clin Oncol 18, 106-115 2000. and GINECO. J Natl Cancer Inst 98,
1036-1045 2006.
148. Ozols, R.F., et al. Phase III trial of
carboplatin and paclitaxel compared with 156. Bookman, M.A., et al. Evaluation of new
cisplatin and paclitaxel in patients with platinum-based treatment regimens in
optimally resected stage III ovarian cancer: advanced-stage ovarian cancer: a Phase III
a Gynecologic Oncology Group study. J Trial of the Gynecologic Cancer
Clin Oncol 21, 3194-3200 2003. Intergroup. J Clin Oncol 27, 1419-1425
2009.
149. Rose, P.G., et al. Secondary surgical
cytoreduction for advanced ovarian 157. Peiretti, M., et al. Role of maximal
carcinoma. N Engl J Med 351, 2489-2497 primary cytoreductive surgery in patients
2004. with advanced epithelial ovarian and tubal
cancer: Surgical and oncological
150. Winter, W.E., 3rd, et al. Prognostic factors outcomes. Single institution experience.
for stage III epithelial ovarian cancer: a Gynecol Oncol 119, 259-264 2010.
Gynecologic Oncology Group Study. J
Clin Oncol 25, 3621-3627 2007. 158. Vergote, I., et al. Neoadjuvant
chemotherapy or primary surgery in stage
151. Spriggs, D.R., et al. Phase III randomized IIIC or IV ovarian cancer. N Engl J Med
trial of intravenous cisplatin plus a 24- or 363, 943-953 2010.
96-hour infusion of paclitaxel in epithelial
ovarian cancer: a Gynecologic Oncology 159. Akeson, M., et al. A population-based 5-
Group Study. J Clin Oncol 25, 4466-4471 year cohort study including all cases of
2007. epithelial ovarian cancer in western
Sweden: 10-year survival and prognostic
152. Winter, W.E., 3rd, et al. Tumor residual factors. Int J Gynecol Cancer 19, 116-123
after surgical cytoreduction in prediction 2009.
of clinical outcome in stage IV epithelial
ovarian cancer: a Gynecologic Oncology 160. Fotopoulou, C., et al. Primary radical
Group Study. J Clin Oncol 26, 83-89 surgery in elderly patients with epithelial
2008. ovarian cancer: analysis of surgical
outcome and long-term survival. Int J
153. du Bois, A., et al. A randomized clinical Gynecol Cancer 20, 34-40 2010.
trial of cisplatin/paclitaxel versus
carboplatin/paclitaxel as first-line 161. Landrum, L.M., et al. Prognostic factors
treatment of ovarian cancer. J Natl Cancer for stage III epithelial ovarian cancer
Inst 95, 1320-1329 2003. treated with intraperitoneal chemotherapy:
a Gynecologic Oncology Group study.
154. du Bois, A., et al. Addition of epirubicin Gynecol Oncol 130, 12-18 2013.
as a third drug to carboplatin-paclitaxel in
first-line treatment of advanced ovarian 162. Polterauer, S., et al. Prognostic value of
cancer: a prospectively randomized residual tumor size in patients with
gynecologic cancer intergroup trial by the epithelial ovarian cancer FIGO stages IIA-
Arbeitsgemeinschaft Gynaekologische IV: analysis of the OVCAD data. Int J
Onkologie Ovarian Cancer Study Group Gynecol Cancer 22, 380-385 2012.
and the Groupe d'Investigateurs Nationaux
pour l'Etude des Cancers Ovariens. J Clin 163. Wimberger, P., et al. Influence of residual
Oncol 24, 1127-1135 20 06. tumor on outcome in ovarian cancer
patients with FIGO stage IV disease: an
OVARIAN CANCER SURGERY - QUALITY INDICATORS
43
